Table 3.

Phase I-II clinical trials investigating SPRMs for breast cancer prevention.

Trial	Interventions	Patient characteristics	Results
Mifepristone
NCT01898312 (123)	mifepristone 50 mg vs. placebo	45 healthy BRCA1/2 carriers	Reduced mitotic age and proportion of luminal progenitor cells in normal breast tissue
Ulipristal acetate
BC-APPS1 trial (123)	ulipristal acetate 5 mg	30 high-risk women	Reduced mitotic age and proportion of luminal progenitor cells in normal breast tissue
NCT02922127 (124)	ulipristal acetate 10 mg vs. combined oral contraceptive	25 young normal-risk women	decreased ki-67 proliferation and reduced background parenchymal enhancement of normal breast tissue
Telapristone acetate
NCT02314156 (127)	Oral vs. topical telapristone acetate 12 mg	60 women undergoing mastectomies	local drug distribution patterns are similar between oral and topical telapristone acetate